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Abbreviations 
CD163  Hemoglobin/haptoglobin scavenger receptor 
CD169  Sialoadhesin, Siglec-1 
CM  Conditioned media 
CSF-1R Colony-stimulating factor 1 receptor 
EGFR  Epidermal growth factor receptor 
ER  Estrogen receptor 
G-CSF  Granulocyte colony-stimulation factor 
G-CSFR Granulocyte colony-stimulating factor receptor 
gMFI  geometric mean fluorescence intensity 
HER2  Epidermal growth factor receptor 2 
IFNγ  Interferon gamma 
LN  Lymph node 
LPS  Lipopolysaccharide 
M1  Classically activated macrophage 
M2  Alternatively activated macrophage 
M-CSF  Macrophage colony-stimulating factor 
MR  Macrophage mannose receptor 
OS  Overall survival 
PgR  Progesterone receptor 
TGF-α  Transforming growth factor alpha 
TNBC  Triple-negative breast cancer 
TAM   Tumor-associated macrophage 
TMA  Tumor micro-array 
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Abstract 
 
Tumor-associated macrophages (TAMs) have been implicated in the promotion of 
breast cancer growth and metastasis, and a strong infiltration by TAMs has been 
associated with estrogen receptor-negative tumors and poor prognosis. However, the 
molecular mechanisms behind these observations are unclear. We investigated 
macrophage activation in response to co-culture with several breast cancer cell lines 
(T47D, MCF-7, BT-474, SKBR-3, Cal-51 and MDA-MB-231) and found that high 
granulocyte colony-stimulating factor (G-CSF) secretion by the triple-negative breast 
cancer (TNBC) cell line MDA-MB-231 gave rise to immunosuppressive HLA-DRlo 
macrophages that promoted migration of breast cancer cells via secretion of TGF-α. In 
human breast cancer samples (n=548), G-CSF was highly expressed in TNBC (P<0.001) 
and associated with CD163+ macrophages (P<0.0001), poorer overall survival (P=0.021) 
and significantly increased numbers of TGF-α+ cells. While G-CSF blockade in the 4T1 
mammary tumor model promoted maturation of MHCIIhi blood monocytes and TAMs 
and significantly reduced lung metastasis, anti-CSF-1R treatment promoted 
MHCIIloF4/80hiMRhi anti-inflammatory TAMs and enhanced lung metastasis in the 
presence of high G-CSF levels. Combined anti-G-CSF and anti-CSF-1R therapy 
significantly increased lymph node metastases, possibly via depletion of the so-called 
“gate-keeper” subcapsular sinus macrophages. These results indicate that G-CSF 
promotes the anti-inflammatory phenotype of tumor-induced macrophages when CSF-
1R is inhibited and therefore caution against the use of M-CSF/CSF-1R targeting agents 
in tumors with high G-CSF expression. 
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Introduction 
 
Breast cancer is one of the leading causes of death in women worldwide. 1 Although 
improvement in both early breast cancer detection and treatment options has reduced 
breast cancer mortality, not all patients have benefited from these advances. Triple-
negative breast cancer (TNBC) is a definition of breast tumors that do not express the 
estrogen receptor (ER) or the progesterone receptor (PgR), and do not have an 
amplification or overexpression of the epidermal growth factor receptor 2 gene (HER2) 
and thus cannot be treated with anti-hormonal therapy or anti-HER2 agents. TNBC 
represents 10-20% of invasive breast cancers and has been associated with African-
American race, younger age, BRCA1 mutations and poorer prognosis. 2 Its heterogeneity 
and the uncharacterized molecular pathways underlying the pathology of TNBC have 
made this breast cancer subtype extremely challenging to treat and manage. 3       
The development of breast cancers, such as TNBC largely depends on the contribution of 
stromal cells in providing growth and metastasis supporting signals as well as aiding 
immune escape from the host. 4 These tumor-supporting actions are vastly mediated by 
tumor-associated macrophages (TAMs) that are abundantly present in the leukocyte 
infiltrate of breast cancers with poor prognosis 5 and ER- negative subtype. 6 In contrast 
to the IFN-γ and lipopolysaccharide (LPS) driven classically activated (M1) macrophages 
with high microbicidal activity, immuno-stimulatory functions and tumor cytotoxicity, 
TAMs resemble the alternatively activated (M2) macrophages, which promote tissue 
repair, angiogenesis, and favor tumor progression. 7 The polarization towards this 
“tolerogenic” phenotype is mainly mediated by the anti-inflammatory cytokines IL-4 and 
IL-13. 8 In response, the M2 polarized macrophages up-regulate several phenotypic 
markers such as macrophage mannose receptor (MR; CD206/MRC1) 9 and 
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hemoglobin/haptoglobin scavenger receptor  CD163 10, and secrete high levels of IL-10. 
11  
Several attempts have been made to inhibit macrophage activation in cancer. 
Macrophage colony-stimulating factor (M-CSF, CSF-1) is a major contributor of TAM 
infiltration and increased tumor growth. 12, 13 Efforts in blocking the M-CSF/CSF-1R 
signaling pathway have been reported to reduce tumor growth in breast cancer 
xenograft models. 14, 15 This, along with other observations of the beneficial effect of 
targeting CSF-1R in various cancers 16-18, has led to the initiation of phase I clinical trials 
with either a monoclonal antibody targeting CSF-1R (IMC-CS4) or a small molecule 
inhibitor of CSF-1R (PLX3397) alone or in combination with chemotherapy to treat solid 
tumors (www.clinicaltrials.gov).  
G-CSF is a cytokine that stimulates the survival, proliferation, differentiation and 
function of neutrophil precursors and mature neutrophils via its receptor G-CSFR. It also 
mobilizes hematopoietic stem cells from the bone marrow and has been utilized for this 
action in hematopoietic stem cell transplantation and in the treatment of chemotherapy-
induced febrile neutropenia. G-CSF has also been reported to modulate inflammatory 
responses since mice pretreated with G-CSF were protected against an otherwise lethal 
dose of LPS. 19 The immune modulatory functions of G-CSF may also potentially be 
mediated by monocyte activation since G-CSF mobilized monocytes carry surface bound 
IL-10 20 and inhibit the release of IL-12 and tumor necrosis factor (TNF)-α after LPS 
stimulation. 21   
In the present study, we found that G-CSF, similar to M-CSF, can modulate monocyte 
differentiation into anti-inflammatory macrophages that have tumor-supporting 
functions. Importantly, we observed that human breast cancer patients with high G-CSF 
expression have a significantly poorer prognosis than low G-CSF expressing patients in 
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TNBC and that this was associated with higher numbers of CD163+ macrophages. In the 
4T1 mouse mammary tumor model, the inhibition of CSF-1R signaling led to increased 
lung metastasis and an abundance of MHCIIlo anti-inflammatory monocytes and TAMs 
when G-CSF was present. However, when G-CSF was also blocked, the incidence of LN 
metastases was dramatically increased, probably due to the anti-CSF-1R mediated 
depletion of subcapsular sinus macrophages.  
  
Results 
 
Alternative activation of human CD14+ monocytes/macrophages by MDA-MB-231 
cells.  
To mimic the interplay between tumor infiltrating monocytes and cancer cells, we 
cultured three human breast cancer cell lines, representing human ER+ (T47D), HER2+ 
(SKBR-3) or triple-negative (MDA-MB-231) breast cancer, in a transwell co-culture 
system with freshly isolated human CD14+ peripheral blood monocytes. In general, the 
single cultured monocytes in RPMI demonstrated a pro-inflammatory phenotype when 
activated by adhesion to the polyester (PET) membrane (Figure S1A). Under co-culture, 
the MDA-MB-231-activated monocytes up-regulated MR (intracellular) and 
demonstrated elongated cell morphology compared to monocytes co-cultured with 
either T47D or SKBR-3 cells (Figure 1A). Quantification of MR expression showed a 
significant increase in MR+/CD68+ cells within the MDA-MB-231 co-culture as compared 
to the other stimuli (Figure 1A; day two P=0.0017, day five P<0.0001). Functionally, the 
MDA-MB-231 educated macrophages developed impaired antigen processing over the 
incubation time as only 15% of cells were able to process fluorescently labeled 
ovalbumin at day five compared to 100% at day two (Figure 1B; P=0.0001).  
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To exclude the effect of adhesion in activating macrophage polarization, the monocytes 
were cultured in ultra-low attachment plates in different cancer cell conditioned media 
collected from three estrogen receptor positive cell lines (T47D, MCF-7 and BT-474) and 
two TNBC lines (Cal-51 and MDA-MB-231). Flow cytometric analysis of cell surface MR 
expression together with HLA-DR expression demonstrated again that only MDA-MB-
231 cells skewed the balance of MR (M2-marker) and HLA-DR (M1-marker) expression 
into an anti-inflammatory phenotype (Figure 1C-E). The polarization difference resulted 
mainly from the down-regulation of HLA-DR on MDA-MB-231 differentiated 
macrophages rather than by an up-regulation of MR expression, at least at the cell 
surface level (Figure 1E; % of CD14+cell positive for HLA-DR P=0.0006 and MR 
P=0.231). Because of the high inter-individual variation in the geometric mean 
fluorescence intensities (gMFIs) of HLA-DR and MR expression, the levels of HLA-DR 
and MR on T47D differentiated macrophages were considered as baseline and used for 
normalization of the data. The individual gMFIs are shown in Figure S1B. 
 
G-CSF promotes differentiation of immunosuppressive HLA-DRlo macrophages. 
To understand why MDA-MB-231 cells promoted HLA-DRlo macrophages in contrast to 
the other cell lines, we screened 48 cytokines, chemokines and growth factors in MDA-
MB-231 CM and compared the secretion profiles to the ones from T47D and SKBR-3 
cells. While MDA-MB-231 cells showed high production of granulocyte colony-
stimulating factor (G-CSF; 5,586 pg/mL), IL-8 (2,425 pg/mL) and VEGF (1,878 pg/mL), 
T47D cells produced high levels of stromal cell-derived factor-1 (SDF-1a/CXCL12; 2,173 
pg/mL) (Figure 2A). Because peripheral blood harvested from G-CSF stimulated donors 
has been reported to contain a skewed Th2 CD4 phenotype and a predominance of type 
2 dendritic cells 22, we investigated whether G-CSF was responsible for the differential 
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activation of co-cultured macrophages by MDA-MB-231 cells. The G-CSF treated 
macrophages increased MR expression and exhibited an elongated cell morphology 
(Figure 2B). After eight days, 99% of CD68+ cells were also MR+ (Figure 2B; P<0.0001). 
Addition of a G-CSF-neutralizing antibody (αG-CSF) to MDA-MB-231 CM decreased the 
amount of MR+/CD68+ cells from 83% to 28% (P=0.0046) after eight days (Figure 2B). 
Again, on the cell surface, MR expression did not dramatically change but HLA-DR 
expression was down regulated on monocytes/macrophages after a four-day treatment 
with G-CSF compared to 1% AB serum treated monocytes (Figure 2C; P=0.032). The G-
CSF differentiated monocytes suppressed CD4+ T-cell activation in response to tetanus 
toxoid, which was seen as a decrease in proliferation (Figure 2D; P=0.019) and lower 
IFNγ production (Figure 2E) of CD4+ T-cells compared to CD4 T-cells co-cultured with 
control monocytes.  
 
G-CSF differentiated macrophages promote cancer cell migration via secretion of 
TGF-α. 
We have previously shown that MDA-MB-231 educated macrophages support tumor 
growth and have an anti-inflammatory phenotype. 23 To test whether G-CSF was also 
responsible for mediating tumor-supporting macrophages in MDA-MB-231 CM, we 
studied cancer cell migration towards control (1% AB), T47D CM, MDA-MB-231 CM and 
G-CSF differentiated macrophages in a co-culture setting where the differentiated 
macrophages served as a source of chemotactic factors for the migrating cells. G-CSF 
polarized macrophages did not change migration of T47D cells compared to control 
macrophages, but the migration was significantly increased towards T47D CM activated 
macrophages (Figure 3A; P<0.0001). G-CSF differentiated macrophages, on the other 
hand, promoted the migration of MDA-MB-231 cells significantly more than 1% human 
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serum or T47D CM differentiated macrophages (Figure 3A; P=0.0076). This suggested 
that G-CSF induced the macrophages to secrete a factor that was chemotactic for MDA-
MB-231 cells, but not for T47D cells. We have previously reported that macrophages up-
regulate transforming growth factor-alpha (TGF-α) and oncostatin M (OSM) transcripts 
in co-culture with MDA-MB-231 cells. 23 TGF-α has been reported to drive triple-
negative tumor invasion 24, whereas OSM promotes EMT and a stem cell-like phenotype 
in breast cancer 25; both factors contribute to tumor aggressiveness. ELISA analysis of G-
CSF-treated macrophage CM at day two indicated that G-CSF significantly increased the 
secretion of TGF-α compared to 1% AB serum or MDA-MB-231 CM differentiated 
macrophages (Figure 3B; P=0.0037) but had no effect on OSM levels (Figure 3B). The 
analysis of epidermal growth factor receptor (EGFR, receptor for TGF-α) expression on 
T47D, MCF-7 (both ER+), Cal-51, and MDA-MB-231 (both TNBC) cells revealed that only 
the TNBC cell lines expressed detectable amounts of EGFR (Figure 3C) explaining why 
only MDA-MB-231 cells increased migration towards macrophages in the presence of 
TGF-α. Since the oncogenic activity of MDA-MB-231 cells is driven by a KRAS mutation, 
we analyzed the feedback loop of G-CSF/TGF-α using the EGFR expressing Cal-51 TNBC 
cell line. In a scratch wound-healing assay, CM from G-CSF differentiated macrophages 
induced Cal-51 migration (wound closure) significantly more than control CM (Figure 
3D; P=0.028). Blockade of TGF-α in the G-CSF CM significantly decreased migration of 
Cal-51 cells compared to IgG CM (Figure 3D; P=0.03). Addition of anti-TGF-α to normal 
growth medium with or without 10% FCS did not affect Cal-51 migration, indicating that 
the Cal-51 cells do not secrete TGF-α in an autocrine manner (data not shown). 
 
High G-CSF expression in human breast cancer is significantly associated with 
TNBC and poorer overall survival.  
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To investigate whether G-CSF was also present in the aggressive types of human breast 
cancer, we stained paraffin-embedded whole tumor sections (Table S1; ER+ n=42; ER- 
n=10) with an antibody against G-CSF to analyze the level and location of this growth 
factor in large tumor areas. Because G-CSF staining of the tumor sections was very 
heterogeneous and mainly located at the invasive front of the tumors, the scoring of G-
CSF staining intensity was done in the invasive areas.  Four scores were assigned (0, 1, 2, 
and 3) where 0 represented negative and 3 high expression of G-CSF, as stated in detail 
in the Methods section and illustrated in Supplemental Figure S2A. For statistical 
analyses, the staining was classified as low (score 0/1) or high (score 2/3) (Figure 4A). 
Of note, the adjacent normal mammary gland demonstrated high G-CSF staining of score 
2 and was used as a positive control to assess staining quality. High G-CSF expression in 
the whole sections was significantly associated with the ER negative subtype (Figure 
S2B; P=0.02) and grade 3 tumors (Figure S2C; P=0.0059). 
In a larger set of human breast cancer samples (n=548), including two tissue 
microarrays (Table 1; TMA21 and TMA174), we detected higher G-CSF expression in the 
triple-negative tumors compared to cancers expressing either ER+ or HER2+ or both. 
(Figure 4B; P<0.001 0/1 vs. 2/3). High G-CSF expression in the TNBC patients was 
significantly correlated with poorer overall survival (OS) when compared to patients 
with low G-CSF expression (Figure 4C; P=0.021). We found an appr. ~13 month 
improvement in the median survival between high and low G-CSF expressing patients at 
50% survival. Because G-CSF levels did not significantly correlate with tumor size 
(P=0.56), grade (P=0.53) or lymph node status (P=0.8, Spearman’s rho), a correction for 
these factors was not done for the G-CSF survival analysis. 
Even though higher G-CSF levels correlated with TNBC, not all TNBC cases 
demonstrated high levels of G-CSF. This might reflect the heterogeneity of TNBC, which 
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has been reported to comprise six different subtypes displaying unique gene expression 
and ontology. 26 According to Lehmann et al., the MDA-MB-231 cell line represents the 
mesenchymal stem-like subtype whereas the Cal-51 cell line represents the 
mesenchymal type of breast cancer. Because the Cal-51 cell line did not induce HLA-DRlo 
macrophages, we analyzed the secretion of G-CSF in Cal-51 cells. There was no 
detectable G-CSF in the conditioned medium of Cal-51 cells similar to the ER+ cell lines 
(Figure 4D), which further confirms the importance of G-CSF in polarizing 
immunosuppressive macrophages. 
In contrast to Cal-51 cells, the MDA-MB-231 cells have a KRAS mutation that leads to 
constitutive activation of the Ras-Raf-MEK-ERK pathway 26, which may increase G-CSF 
secretion. 27 Indeed, selective inhibition of MEK1/2 in MDA-MB-231 cells by RDEA119 
resulted in a significant reduction in G-CSF secretion after 24 hours compared to the 
DMSO control (Figure 4E; P<0.0001). At this time point, no significant effect on cell 
viability was seen (Figure 4E). After 48 hours, G-CSF was undetectable in the RDEA119 
treated MDA-MB-231 cells but also cell viability was decreased significantly (Figure 4E; 
P<0.0001).   
 
High G-CSF expression in triple-negative breast cancer patients is associated with 
an abundance of CD68+CD163+ macrophages and TGF-α+ cells.  
To investigate the possible effects of high G-CSF expression on the phenotype of tumor-
associated macrophages (TAMs), we analyzed the TAMs in the high and low G-CSF 
expressing triple-negative breast cancers. We stained the same tissue arrays for TAMs 
using antibodies against CD68 (Figure 4F) and the widely used M2 macrophage marker 
CD163 (Figure 4G). We chose to use CD163 instead of MR since we did not see a clear 
up-regulation of MR on tumor-conditioned macrophages, and CD163 expression on 
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TAMs has been reported to associate with poor prognosis in human breast cancer. 28 
CD163 staining significantly correlated with CD68 staining (Figure 4F; P<0.0001), 
indicating that the CD163+ cells were indeed macrophages. Among the TNBC patients, 
we found more CD163+ cells in the high G-CSF expressing tumors than in the low G-CSF 
expressing tumors (Figure 4G; P<0.0001), suggesting that G-CSF might have a local 
effect in supporting M2-like macrophages in human breast cancer. High G-CSF 
expressing tumors also demonstrated a significantly higher number of TGF-α+ cells 
(Figure 4H; P=0.0069). The analysis for TGF-α+ cells was done on whole sections to have 
a more detailed analysis of the number and location of these cells. Interestingly, most of 
the TGF-α+ cells resided in the invasive area in close vicinity to large blood vessels. 
 
G-CSF and M-CSF differentiated macrophages show similar phenotypes with the 
exception of CD16 expression.  
To specify the human monocyte population responding to G-CSF signals, we measured 
the cell surface expression of G-CSF receptor (G-CSFR) on three different monocyte 
populations based on the expression of CD14 and CD16 by flow cytometry. G-CSFR was 
expressed on the surface of approx. 20% of the classical CD14+CD16- monocytes and 
was reduced gradually upon monocyte maturation (CD16+) (Figure 5A). When 
stimulated with G-CSF, however, the CD14+CD16- cells significantly up-regulated CD16 
expression compared to M-CSF or 1% normal human (AB) serum treated monocytes at 
day five (Figure 5B; P=0.0081), indicating that G-CSF promoted monocyte maturation 
into non-classical resident CD16+ macrophages. Both G-CSF and M-CSF increased cell 
surface MR expression when compared to 1% AB serum but G-CSF was more effective 
than M-CSF at the same concentration (Figure 5B; P=0.007). No significant changes were 
observed in the cell surface expression of CD11c and CD86 (Figure 5B); however, G-CSF 
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induced a slight but significant increase in CD80 expression compared to 1% AB serum 
treated macrophages (Figure 5B; P=0.0081). Morphologically, the G-CSF treated 
macrophages represented a more homogenous population than the M-CSF treated 
macrophages (Figure 5C). Because only a subpopulation of monocytes expressed G-
CSFR, cell death during macrophage differentiation using G-CSF was observed. No 
significant difference was seen in the ability to process fluorescently labeled ovalbumin 
(Figure 5D).  
 
Both G-CSFR and CSF-1R are expressed on tumor-induced CD11bLy6C+Ly6G+ 
myeloid cells and systemic CSF-1R blockage promotes metastasis in the 4T1 
mammary tumor model. 
The effect of G-CSF on human monocytes prompted us to investigate how TAMs respond 
to high levels of G-CSF when the M-CSF/CSF-1R signaling route is inhibited in vivo. To 
this end, we used the well established 4T1 mammary tumor model 29 that is known to 
secrete high levels of G-CSF. 30 Administration of 10 mg/kg of anti-CSF-1R every second 
day promoted tumor growth (Figure 6A; P=0.0005) and enhanced metastasis to the 
draining inguinal (P=0.032) and axillary (P=0.0063) lymph nodes as well as to the lung 
(P=0.0083) compared to control IgG treated mice (Figure 6B). In this setting, the anti-
CSF-1R antibody prevented M-CSF from binding to CSF-1R because the serum levels of 
M-CSF increased substantially compared to control IgG treated mice (Figure 6C; 
P<0.0001). Interestingly, both monocyte (P=0.012) and neutrophil (P=0.0047, data not 
shown) populations were increased in the blood of anti-CSF-1R treated mice compared 
to control mice (Figure 6D). The anti-CSF-1R did not reduce the number of peritumoral 
F4/80+ macrophages and these macrophages were also highly MR positive (Figure 6E; 
P=0.021).  
D
ow
nl
oa
de
d 
by
 [T
ur
ku
 U
niv
ers
ity
] a
t 2
3:3
1 2
4 N
ov
em
be
r 2
01
5 
  14 
To investigate which cell populations were targeted by anti-CSF-1R treatment, we 
analyzed both CSF-1R and G-CSFR cell surface expression on peripheral blood myeloid 
cells in non-tumor bearing and 4T1 tumor-bearing mice. For the detection of G-CSFR, we 
used an approach previously reported by Mitsui et al., where human recombinant G-CSF 
was conjugated and used in flow cytometry for the detection of mouse G-CSFR. 31 To 
verify specific binding of the conjugated G-CSF to its receptor, we stained the 
CD11bLy6C+Ly6G- monocytes (Q1) and CD11bLy6+Ly6G+ granulocytes (Q3) from 
peripheral blood of G-CSFR wild type (WT) and knockout (KO) mice (Figure 6F). The KO 
mice clearly had a reduction of the number of Ly6G+ cells, verifying the KO phenotype. 
The KO granulocytes did not bind the conjugated G-CSF, in contrast to the WT 
granulocytes, indicating proper binding of G-CSF (Figure 6F).  
CSF-1R expression in non-tumor mice was only detected on Ly6C+Ly6G- monocytes. 
These cells were also slightly positive for G-CSFR (Figure 6G, upper panels). 
Surprisingly, the tumor-bearing mouse population consisted only of Ly6C+Ly6G+ cells 
that remained CSF-1Rint/hi and had increased expression of G-CSFR (blue line, Q2) 
compared to CSF-1R- granulocytes (grey-filled line, Q3) (Figure 6G, lower panels).  
 
Blockade of both CSF-1R and G-CSF promotes inflammatory TAMs and reduces 
lung metastasis but promotes lymph node metastasis via depletion of CD169+ 
subcapsular sinus macrophages. 
Anti-G-CSF treatment in the 4T1 model has been previously shown to reduce peripheral 
mobilization of CD11b+Gr1+ cells and reduce metastasis to the lung. 32, 33 In our model, 
we observed a slight decrease in tumor growth when anti-G-CSF (0.6 mg/kg) treatment 
was administered every second day (Figure S3A; P<0.05 day 21). This anti-G-CSF 
treatment regimen resulted in an almost complete neutralization of G-CSF within the 
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serum of tumor bearing mice (Figure S3B; P<0.0001). Moreover, the tumor-induced 
mobilization of blood monocytes (P=0.0002) and neutrophils (P<0.0001) was 
normalized by anti-G-CSF treatment (Figure S3C). Ex vivo isolated TAMs from anti-G-CSF 
treated mice were almost completely negative for intracellular MR and showed the 
typical morphology of M1 macrophages (Figure S3D). The anti-G-CSF treated TAMs also 
processed fluorescently labeled ovalbumin more efficiently (Figure S3E), which was 
seen as a significant rightward shift of the fluorescence intensity in the cumulative 
frequency plot (Figure S3E; P<0.0001). Since the anti-G-CSF treatment also reduced Gr1+ 
cells in the tumors and lungs (Figure S3F), we specifically depleted Ly6G+ cells from the 
4T1 tumor mice (Figure S4A) to exclude the effects of Ly6G neutrophils on tumor 
promotion during anti-G-CSF therapy. Tumor growth (Figure S4B) and metastasis 
(Figure S4C) were not changed after depleting the Ly6G+ cells compared to the IgG 
controls.  
We next treated the tumor bearing mice with a combination of anti-G-CSF and anti-CSF-
1R to specifically determine how G-CSF induced metastasis when CSF-1R was inhibited. 
We increased the dose of anti-G-CSF to 1 mg/kg since anti-CSF-1R treatment has been 
reported to increase G-CSF levels in the 4T1 model. 34 Anti-G-CSF as a single agent 
significantly reduced tumor growth (Figure 7A; P=0.0007), lung metastasis incidence 
(P=0.01) and burden (P=0.048) compared to IgG control mice (Figure 7B). Blockade of 
both G-CSF and CSF-1R did not reduce primary tumor growth (Figure 7A) but partly 
reduced lung metastasis incidence (Figure 7B). Unexpectedly, the mice that received the 
combination treatment demonstrated significantly increased metastasis to the tumor-
draining LNs compared to the other treatments (Figure 7B; inguinal lymph nodes 
P=0.027, axillary lymph nodes P=0.0075).  
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Within the peripheral blood, anti-G-CSF and combination (anti G-CSF and anti-CSF-1R) 
treatment reduced the number of CD11b cells (Figure 7C; P=0.0009) and normalized 
monocyte maturation compared to anti-CSF-1R only (Figure 7C; red gates, Ly6Cint 
P=0.0003, Ly6Clo P=0.0006). However, the combination treatment did not induce MHCII 
expression on Ly6Cint/hi monocytes, as did anti-G-CSF (Figure 7C; blue gates, Ly6Chi 
P=0.0002, Ly6Cint P=0.0006), indicating that the inflammatory monocyte population 
could not be activated when both signals were omitted. The combination treatment also 
significantly reduced the number of Ly6CloMHCIIlo anti-inflammatory TAMs compared to 
anti-CSF-1R treatment (Figure 7D; red gates, P=0.0005). Interestingly, anti-G-CSF 
treatment induced three TAM populations, one with Ly6CintMHCIIlo expression (Figure 
S5B). This population was the only one that showed a difference in the expression levels 
of F4/80 and MR between the different treatments. The F4/80 and MR expression on 
this population was promoted by G-CSF since the induction of F4/80 expression by anti-
CSF-1R treatment could be blocked by the combination treatment (Figure 7D; blue 
gates, F4/80 P=0.035, MR n.s.).  
These results suggest that there are different mechanisms that facilitate lung metastasis 
in comparison to LN metastasis. This was evident from the different patterns that were 
seen either when G-CSF or CSF-1R was inhibited. Since anti-CSF-1R treatment also 
targets macrophages outside of tumors, we investigated the effects of anti-CSF-1R on 
CD169+ subcapsular sinus macrophages. We observed a depletion of CD169+ cells in the 
subcapsular sinus area in all LNs treated either with anti-CSF-1R or combination 
treatment (Figure 7E), possibly facilitating tumor cell entry into the lymph node tissue 
in the absence of the gate-keeper macrophages. 
Discussion 
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In this study, we identify an important role for G-CSF in modulating the phenotype of 
anti-inflammatory monocytes and TAMs in both human and mouse tumors. While the 
ER+ and HER2+ subtype of human breast cancers demonstrated low levels of G-CSF 
staining, TNBC with high levels of G-CSF were associated with increased CD163+ 
macrophage numbers and decreased overall survival compared to low G-CSF expressing 
tumors. Our data are in accordance with reports indicating that – apart from its 
beneficial effect – G-CSF also mediates T-cell tolerance 35, suppression of dendritic cell 
differentiation 36, and facilitates neoplastic growth 30, metastasis 32 and refractoriness to 
anti-VEGF treatment 33 through a granulocytic myeloid-derived suppressor cell 
mechanism. High levels of tumor-secreted G-CSF have been reported in some sporadic 
cases of aggressive human tumors 37-39 and more recently, high expression of G-CSF and 
G-CSFR was reported in colon and gastric cancer, where G-CSF promoted carcinoma cell 
proliferation and migration. 40  
Elevated G-CSF secretion in human TNBC most likely arises from the different activation 
of driver mutations in these tumors that are not present in ER+ breast cancers. For 
example, mouse breast cancer cell lines with constitutive activation of the Ras-Raf-MEK 
pathway produce pronounced amounts of G-CSF. 27 Since we did not detect high G-CSF 
in the conditioned medium of the Cal-51 cell line and G-CSF was also heterogeneously 
expressed among the TNBC patients, we propose that only a part of cells with acquired 
KRAS mutation may have the ability to produce pathological amounts of G-CSF, which 
importantly can be targeted by inhibiting Ras downstream signaling using the MEK1/2 
inhibitor. The fact that normal mammary glands also expressed G-CSF highlights the 
possibility that different mechanism(s) exist for the secretion of G-CSF from TNBC and 
non-malignant cells. One possibility is the difference in microenvironments where G-CSF 
is present, such that in TNBC other stromal cells and secreted molecules contribute to 
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enforce the immunosuppressive activity of G-CSF. Another possibility is alternative 
splicing of the CSF3 gene, which generates at least three different forms of the G-CSF 
protein. 41 This might lead to different soluble or membrane bound forms of G-CSF that 
have different activities on stromal compartments, similar to what has been reported for 
M-CSF. 42  
In our study G-CSF differentiated CD14+ monocytes expressed lower levels of HLA-DR 
and inhibited CD4 T-cell activation in response to tetanus toxoid. These cells were also 
able to promote migration of Cal-51 cells via secretion of TGF-α. The effect of G-CSF in 
activating TGF-α secretion was further supported by our clinical data where a 
significantly higher number of TGF-α+ single cells were found in tumors with high 
expression of G-CSF. The MDA-MB-231 produced G-CSF did not activate TGF-α secretion 
similar to the recombinant protein, which might result from the lower levels of G-CSF in 
MDA-MB-231 CM (5.5 ng/mL) vs. recombinant G-CSF (40 ng/mL). The MDA-MB-231 CM 
contains also many other factors that might inhibit TGF-α up-regulation on macrophages 
directly or indirectly via other signaling molecules. Along with this notion, the multitude 
of molecules secreted by MDA-MB-231 cells might activate macrophages to secrete 
molecules that can also be chemotactic for T47D since a migratory response of T47D 
cells to MDA-MB-231 CM differentiated macrophages was observed.  
TGF-α is a growth factor that binds the epidermal growth factor receptor (EGFR) and 
activates several pathways (PI3K-Akt-mTOR and Ras-Raf-MEK-ERK) that mediate cell 
proliferation, migration, invasion and angiogenesis. EGFR is more commonly expressed 
by basal-like and TNBC cancers 43 and associates with low hormone status, higher 
proliferation, genomic instability and reduced disease-free survival. 44 Our analysis of 
EGFR expression in ER+ and TNBC cell lines demonstrated that only Cal-51 and MDA-
MB-231 cells expressed detectable amounts of EGFR. Thus, both cell lines are able to 
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respond to macrophage secreted TGF-α. The MDA-MB-231 cell line, however, does not 
need reinforcement of EGFR signaling by TGF-α since the Ras pathway is constitutively 
activated. As the Cal-51 cells did not basally secrete G-CSF it remains to be investigated 
whether these cells would up-regulate G-CSF when activated by TGF-α. There could also 
exist a “parallel” paracrine signaling loop where secretion of G-CSF by one type on 
cancer cell would end up activating another type of cancer cell with EGFR expression. 
Since many other tumor stromal components can secrete G-CSF 45, the induction of TGF-
α expression by macrophages may not necessarily be always cancer cell driven. This 
notion also raises the possibility that G-CSF therapy used to treat febrile neutropenia of 
some breast cancer patients may have adverse effects in promoting tumor cell migration 
via activation of TAMs to secrete TGF-α. 
M-CSF is the major growth factor for blood monocytes to mature into tissue 
macrophages and has been extensively studied as a drug target. We found that inhibiting 
the M-CSF/CSF-1R signaling axis in the 4T1 model significantly increased metastasis to 
the tumor draining LN and lung. A recently published study described similar findings 
after antibody or small molecule based targeting of M-CSF and CSF-1R in the 4T1.2 and 
EMT6.5 breast cancer models. 34 In this paper, the authors concluded that the increased 
lung metastasis might have been a result of increased G-CSF mediated recruitment of 
neutrophils and Ly6Chi monocytes in the peripheral blood because no changes of TAM 
numbers were observed. Our study now shows that, indeed, G-CSF potently mediated 
metastasis to the lung via recruitment of anti-inflammatory Ly6Chi/intMHCIIlo peripheral 
blood monocytes. Additionally we show that G-CSF mediates differentiation of 
Ly6CloMHCIIlo anti-inflammatory TAMs when CSF-1R is inhibited. This suggests that in 
the presence of high G-CSF, the tumor-recruited monocyte populations are not 
dependent on M-CSF for their survival and differentiate according to G-CSF-generated 
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anti-inflammatory cues. This goes along with our observation that tumor-induced 
mouse myeloid cells express both CSF-1R and G-CSFR in contrast to the normal situation 
where CSF-1R is expressed solely on CD11bLy6C+Ly6G- and G-CSFR mainly on 
CD11bLy6C+Ly6G+ cells. Depletion of Ly6G+ cells did not significantly affect primary 
tumor growth or metastasis to the inguinal and axillary lymph nodes and lungs. Also, 
Granot. and colleagues showed that G-CSF induced neutrophils do not have any effect on 
lung foci formation in an experimental metastasis model. 46 They also showed that 
depletion of Ly6G+ increased metastasis to the lung rather than inhibited it. Thus, we 
conclude that the effects of G-CSF in promoting metastasis would be orchestrated by 
M2-like macrophages and/or MHCIIlo anti-inflammatory monocytes. 
Importantly, we found a striking increase in LN metastasis burden in mice treated with 
anti-G-CSF in combination with anti-CSF-1R. We propose that the increased metastasis 
was promoted by the almost complete depletion of CD169+ subcapsular sinus 
macrophages in the tumor-draining LNs of the combination treated mice. In fact, a 
similar but subtler effect was seen already when anti-CSF-1R was used as a single agent, 
possibly indicating that CSF-1R is a major growth factor for subcapsular sinus CD169+ 
macrophages even in the presence of high levels of G-CSF. CD169+ macrophages are 
important gate-keeper cells lining the lymphatic endothelial wall on the subcapsular 
sinus where they prevent systemic pathogen dissemination. The importance of CD169+ 
macrophages in anti-tumor responses was demonstrated by Asano and colleagues 47 
where mice lacking CD169+ macrophages in the tumor-draining LN failed to generate 
anti-tumor immunity via activation of tumor-specific CD8+ T-cells. Moreover, in human 
clinical samples, a high number of CD169+ macrophages in the regional LNs of colorectal 
carcinoma 48 and malignant melanoma patients 49  was associated with longer overall 
survival.  
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In conclusion, our results reveal that aggressive breast cancers secrete high amounts of 
G-CSF that educates tumor-infiltrating monocytes to promote tumor growth by skewing 
them to an anti-inflammatory phenotype with enhanced secretion of TGF-α (Figure 
S5C). Therefore, patients with high G-CSF producing tumors might benefit from anti-G-
CSF treatment to reduce Th2-activated myelopoiesis and inhibit metastatic seeding, 
which should be investigated in future clinical studies. Our results also indicate that 
tumor G-CSF levels should be taken into consideration when using M-CSF/CSF-1R 
blocking agents to deplete macrophages in breast cancer.  
Materials and Methods 
 
Isolation of human peripheral monocytes and differentiation assays 
Peripheral blood mononuclear cells were isolated from buffy coats from healthy donors 
(Blutspende Zürich, Zurich, Switzerland) by density gradient centrifugation using Ficoll-
paque PLUS (Cat: 17-1440-02; GE Healthcare). The monocyte population was 
magnetically enriched by negative selection using the Human Monocyte Isolation Kit II 
(Cat: 130-091-153; MACS, Miltenyi Biotech). The monocyte purity was >95% as 
confirmed by FACS analysis with an anti-CD14 antibody (BD Biosciences). 
Freshly isolated human monocytes were differentiated into macrophages by incubation 
with either 50 ng/mL of human M-CSF (Cat: 14-8789) or G-CSF (Cat: 578602)  (both 
from BioLegend) in RPMI medium (Cat: 61870-010; Gibco) supplemented with 1% heat 
inactivated human AB serum (Cat: 34005100; Invitrogen), for up to eight days. 20 
ng/mL of recombinant human IL-4 (Cat: 204-IL; R&D Systems) was used as a control to 
induce M2-type macrophage differentiation and anti-human G-CSF (1 μg/mL, clone 
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BVD13-3A5, Cat: 502101; BioLegend) or isotype control (rat IgG1 Cat: 400401) was 
used to neutralize G-CSF in MDA-MB-231 conditioned medium.  
 
Cell lines and conditioned media (CM) 
T47D, SKBR-3 and MDA-MB-231 (kindly provided by Dr. Nancy E. Hynes, FMI, Basel, 
Switzerland), MCF-7, BT-474 and Cal-51 (kindly provided by Prof. Pirkko Härkönen, 
University of Turku, Turku, Finland) were maintained in RPMI medium supplemented 
with 10% fetal bovine serum. According to published data, the T47D and MCF-7 cell 
lines are ER+HER2-, the BT-474 cells line is ER+HER2+, the SKBR-3 cell line is ER-HER2+, 
and the Cal-51 and MDA-MB-231 cell lines are ER-HER2-.26, 50 Before experimentation, all 
cell lines were tested negative for mycoplasma with MycoProbe (Cat: CUL001B; R&D 
Systems). To produce conditioned media (CM), cancer cells were plated at a density of 
2x106 cells in 10 cm cell culture plates. The next day, cells were washed twice with PBS 
and incubated with RPMI medium only. Cell cultures or empty culture plates (control) 
were incubated at 37°C for 24 hours. The medium was collected, filtered through a 0.22 
μm syringe and stored at -80°C if not used fresh. 
 
Transwell co-culture assay 
Cancer cells were seeded into the lower compartment of 12 well transwell polyester 
(PET) permeable supports, pore size 0.4 μm (Cat: 3470; Corning; 5x104 cells/well) and 
were incubated overnight in RPMI supplemented with 10% FBS. Then, cells were 
washed with PBS and incubated in RPMI for one hour before adding 5x104 freshly 
isolated human peripheral monocytes into the upper compartment of the transwell 
inserts. The co-cultures were incubated for up to eight days in a humidified chamber at 
37°C. 
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Immunofluorescence staining 
Human monocytes/macrophages were fixed with methanol and stained with anti-CD68 
(clone PG-MI, Cat: M 0876; Dako; 1:100) and anti-CD206 (MR) (clone 309210, Cat: 
MAB2534; R&D Systems; 1:100) antibodies diluted in Antibody Diluent (Zytomed 
Systems). The signal was detected using Alexa Fluor 488 and 594 conjugated secondary 
antibodies (Molecular Probes) and the samples were imaged with an Axioskop 2 mot 
plus fluorescence microscope equipped with Plan-APOCHROMAT 20×/0.8 NA and 
40×/0.95 NA objectives and an AxioCam MRc camera with AxioVision software 4.7.1 
(Carl Zeiss AG). The staining intensity was quantified using ImageJ software and the 
percentage of CD68+ cells that were also MR-positive was determined. 
Frozen tumors sections (7 μm) were stained with anti-F4/80 (clone C1:A3-1, Cat: 
ab6640; Abcam; 1:100) and anti-MR (Cat: AF535; R&D Systems; 1:250) antibodies, and 
tumor-draining LNs with anti-CD169 antibody (clone 3D6.112, Cat: MCA884F; Serotec; 
1:100) as described above. 
Flow cytometric analysis of activation markers on monocytes/macrophages 
Human monocytes/macrophages were cultured either in ultra-low attachment 96-well 
plates (1x105 cells, Cat: 7007; Corning) or in 6-well plates (5x105 cells) in CM or in 
medium supplemented with M-CSF and G-CSF up to eight days. The adherent 
macrophages were detached using 10 mM EDTA in PBS and gentle scraping. Primary 
antibodies and the Fc-blocking anti-human antibody (Cat: 14-9161, eBioscience) were 
diluted in FACS buffer (PBS with 1% BSA and 2 mM EDTA). The pelleted cells were pre-
incubated with the Fc-block for 10 min and thereafter stained with the following 
antibodies at 1:200 dilution for 30 min on ice in dark: CD14-Pacific blue or -FITC (clone 
M5E2, Cat: 558121 or 557153), CD16-PE (clone 3G8, Cat: 555407), MR-APC (clone 19.2, 
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Cat: 550889), HLA-DR-FITC (clone Tu39, Cat: 555558), CD11c-PE (clone B-ly6, Cat: 
555392) (all from BD Biosciences), CD86-FITC (clone BU63, Cat: MCA1118F, AbD 
Serotec) and CD114-PerCP/Cy5.5 (G-CSFR; clone LMM741, Cat: 346109; BioLegend). 
The cells were washed twice with FACS buffer and analyzed immediately with a FACS 
Canto or LSR Fortessa Flow Cytometer (Becton Dickinson and Company) using the FACS 
Diva software. FlowJo software (v9.3.2) was used to analyze the data. The expression 
levels of activation markers were reported as the difference between the geometric 
mean fluorescence intensity (gMFI) with a specific antibody and the isotype control 
gMFI. 
Mouse monocytes/macrophages were stained as above using the CD16/CD32 Fc-block 
(clone 2.4G2, Cat: 553142; BD) and the following antibodies: CD45-PerCP-Cy5.5 (clone 
30-F11, Cat: 550994; BD), CD11b-APC or -APC-Cy7 (clone M1/70, Cat: 553312 or 
561039; BD), Ly6G-BV510 or –PE (clone 1A8, Cat: 127633; Biolegend or Cat: 551461; 
BD), Ly6C-BV421 (cloneAL-21, Cat: 562727; BD), I-A/I-E—BV510 or -PE-Cy7 (clone 
M5/114.15.2, Cat:107635; Biolegend or 25-5321-82; eBioscience), F4/80-Alexa647 
(clone A3-1, Cat: MCA497A647; AbD Serotec), CD206-Alexa488, CD115-PE-Cy7 (clone 
AFS98, Cat: 25-1152-80; eBioscience) and analyzed with an LSR Fortessa Flow 
Cytometer (BD).  
The recombinant human G-CSF was conjugated with Alexa Fluor 488 using the Alexa 
Fluor 488 microscale protein labeling kit (A30006, Molecular Probes) according to the 
manufacturer’s protocol. The conjugated recombinant protein was used similar to the 
directly conjugated antibodies in flow cytometry. 
   
Ovalbumin processing  
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DQ-Ovalbumin BODIPY FL (10 μg/mL, Cat: D12053; Molecular Probes) was added to cell 
cultures two hours before fixing the cells with ice-cold methanol. For human 
macrophages, the intracellular processed ovalbumin was quantified on the basis of OVA 
positive/negative cells by fluorescence microscopy or by flow cytometry.  
 
Multiplex assay and ELISA  
Conditioned media (serum-free) were analyzed for cytokine, chemokine and growth 
factor production using Bio-plex pro assay Human Cytokine 21-plex (Cat: MF0-005KMII) 
and Human Cytokine 27-plex (Cat: M50-0KCAF0Y) (BioRad) according to the 
manufacturer’s instructions. 
G-CSF levels in conditioned media of 4T1 cells and in mouse serum samples were 
measured according to the manufacturer’s instructions (Cat: ELM-GCSF; RayBiotech) at 
a  1:50 dilution. Human G-CSF was measured in undiluted cancer cell CM using the 
Human G-CSF Quantikine ELISA-component kit (Cat: DCS50, R&D Systems). TGF-α (Cat: 
100646) and oncostatin M (OSM, Cat: ab100619) levels in human 
monocyte/macrophage conditioned media (undiluted) were measured using human 
ELISA kits according to the manufacturer’s instructions (Abcam). 
 
Tetanus toxoid response in CD4 T-cells 
Monocytes (positive selection, CD14 monocyte enrichment kit, Miltenyi Biotech) and 
CD4+ T-cells (negative selection, CD4 T-cell enrichment kit, EasySep) were enriched 
from the same donors vaccinated within the past 3 years with tetanus toxoid. The 
monocytes were isolated four days prior to T-cells to differentiate them either with 1% 
human serum or 50 ng/mL of G-CSF in low attachment 96-well culture plates. On the 
day of T-cell isolation, the differentiated monocytes were plated at a density of 3x104 
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cells in 96-well flat bottom plates and let to adhere for one hour. The monocytes were 
then pulsed with 20 μg/mL of tetanus toxoid (a kind gift from Dr. Olli Lassila, 
Department of Medical Microbiology, University of Turku, Turku, Finland) three hours 
prior to the addition of 3x105 of CFSE labeled CD4+ T-cells in a medium containing RPMI, 
10% FCS, 2 mM L-glutamine and 100 μM β-mercaptoethanol. For labeling T-cells with 
CFSE (Vybrant CFDA SE cell tracer kit, Cat: VI2883, Molecular Probes), a concentration 
of 1 μM CFSE for 5 minutes at 37°C for 1x106 cells/mL was used.  
96-well ELISpot plates (Mabtech) were coated with anti-human IFNγ (1 μg/mL) for 2 
hours at 37°C, washed with PBS and blocked with 10% FCS in RPMI. The enriched 
monocytes and CD4 T-cells were co-cultured in the precoated ELISpot wells in 
triplicates at a ratio of 1:10 (1x104 monocytes and 1x105 T-cells). After three days, the 
wells were washed and incubated with biotinylated anti-IFNγ and alkaline phosphatase-
conjugated anti-biotin secondary antibody (1:1000). Spots were developed with 
BCIP/NBT solution and counted microscopically. The number of spots from tetanus 
toxoid activated co-cultures were normalized to the spot count of wells containing T-
cells only, T-cells with tetanus toxoid and T-cells with monocytes but without tetanus 
toxoid. 
 
Migration assay 
Freshly isolated monocytes (5x104) were incubated in 24 well plates with 1% AB serum, 
T47D CM, MDA-MB-231 CM, or 40 ng/mL human recombinant G-CSF (Cat: 561701; 
eBiosciences) in 1% AB serum for 48 hours. Thereafter, the cells were washed with PBS 
and incubated for 24 hours in RPMI. After this, either 2x104 T47D or MDA-MB-231 cells 
were added on top of the polarized macrophages in collagen pre-coated transwell 
inserts with a pore size of 8 μm (Corning). The transwell inserts were coated according 
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to the protocol from Corning with Type I Collagen Solution from Rat Tail (Cat: C3867; 
Sigma). The cells were let to migrate for six hours. The migrated cells were visualized by 
Hoechst staining and counted under a microscope in five different visual fields per 
insert. Each condition was done in triplicates.  
 
Western blot 
SDS-PAGE and Western blotting for EGFR detection (sc-03, 1:1000 dilution; Santa Cruz) 
on cancer cell lysates (50 μg/well) was performed using standard procedures. The anti-
EGFR signal was detected using IRdye680 donkey anti-rabbit (Cat: 925-68073; LiCOR) 
and imaged using the LiCOR Odyssey CLx system. Anti-tubulin (TUB 2.1, sc-58886; Santa 
Cruz) was used simultaneously as a loading control and detected by IRdye800 donkey 
anti-mouse (Cat: 925-32212; LiCOR).  ChameleonDuo Pre-stained Protein Ladder (Cat: 
P/N 928-60000; LiCOR) was used as a protein standard. 
 
Scratch wound healing assay 
Cal-51 cells were plated on ImageLock 96-well plates (Cat: 4379, Essen Bioscience) as a 
confluent layer (4x104 cells). A scratch wound was made to each well the next day, using 
a 96-pin wound-making tool (Wound MakerTM, Essen Bioscience). The medium was 
replaced by CM collected from monocytes grown in control medium (RPMI only) or 50 
ng/mL of G-CSF for four days and added as a 1:2 dilution in RPMI supplemented with 
1% FCS. 5 μg/mL of anti-TGF-α antibody (Cat: ab9585, Abcam) or isotype control 
(rabbit IgGs) was added to the CM before experimentation. Each condition was studied 
in triplicates. Anti-TGF-α antibody in medium supplemented with or without 10% 
serum in RPMI was found to have no effect on Cal-51 migration compared to isotype 
control. Cal-51 migration was scanned every two hours with a 10x objective by the 
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Incucyte ZOOM system (Essen Bioscience) for a total of 48 hours at 37°C. Wound width 
was analyzed from the scanned images using the Essenbio software. The assay was 
performed using CM collected from three different donor monocytes. 
 
Human samples 
Human breast cancer tissue was obtained from the diagnostic service of the Institute of 
Surgical Pathology, University Hospital Zürich, Zurich, Switzerland. For large sections, 2 
μm thick sections from 52 cases of paraffin embedded breast cancer samples with 
adjacent normal breast tissues were used. Tissue micro arrays (TMA) were constructed 
as described previously. 51 TMA21 contained breast cancer spots from 475 consecutive 
breast cancer cases and TMA174 contained 91 spots from hormone receptor negative 
breast cancers where 83 cases were also triple-negative. Patient demographic data of 
the TMAs are presented in Table S1. The study on human breast cancer tissues was 
approved by the local ethical committee (KEK-Nr. 2012-553) and by the internal review 
board of the Institute of Surgical Pathology, University Hospital Zürich, Zurich, 
Switzerland. 
 
Immunohistochemical stainings 
Human paraffin-embedded sections/tumor micro-arrays were stained with primary 
antibodies for G-CSF (Cat: ab9691, Abcam; 1:400), CD163 (clone 10D6, Cat: NCL-CD163, 
Novocastra; 1:50) or TGF-α (Cat: ab112030, Abcam; 1:300) using citrate buffer (pH 6) 
antigen retrieval, and for CD68 (clone PG-M1, Cat: M0876, DakoCytomation; 1:200) 
using EDTA pH 9.0 antigen retrieval, a 1:200 dilution of biotinylated anti-rabbit or 
mouse secondary antibodies, the ABC kit, and 3-amino-9-ethylcarbazole (AEC) 
peroxidase substrate (all from Vector Laboratories). The slides were evaluated and 
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scored by two observers blinded to sample identity. If the two observes disagreed in 
scoring, the samples were re-evaluated by a third blinded observer. Scoring of G-CSF 
staining was done semi quantitatively as follows: score 0, no reactivity; score 1, weak 
cytoplasmic reactivity in <50% of the tumor surface; score 2, moderate cytoplasmic 
reactivity in >50% of the tumor surface; score 3, strong cytoplasmic reactivity in >50% 
of the tumor surface. Representative staining areas from different scoring is shown in 
Supplemental Figure S2A. The scoring for CD68 staining was done with a cut-off of 30% 
stained area, low representing <30% coverage and high representing ≥30% coverage of 
the tumor-array spot. 
 
MEK inhibitor treatment and cell viability assay 
MDA-MB-231 cells were plated at a density of 1x104 cells in 96-well flat-bottom cell 
culture plates (Corning). The next day, the cells were starved for 4 hours in RPMI 
medium only before the addition of 10 nM or 1 μM of the MEK1/2 inhibitor RDEA119 
(Cat: 1089), the MEK5 inhibitor BIX02189 (Cat: S1531) (both from Selleckchem) or a 
similar volume of DMSO for 24-48 hours. The medium was collected for G-CSF ELISA 
analysis after 24 and 48 hours and replaced by 100 μL of RPMI containing 10 μL of the 
CCK8 reagent (Cat: CK04-11, Dojindo) for cell viability analysis. All experiments were 
performed in triplicates with 3-4 repetitions. The G-CSF level for each well was 
normalized to the corresponding absorbance signal. 
 
4T1 mammary tumors 
All animal experiments were approved by the cantonal veterinary office Zurich 
(Kantonales Veterinäramt Zürich; protocol 11/2012) or The Finnish Act on Animal 
Experimentation (62/2006), performed in compliance with the 3Rs principle and 
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accepted by the local Committee for Animal Experimentation (animal license number 
5587/04.10.07/2014). The G-CSFR KO mice (B6.129X1(Cg)-Csf3rtm1Link) were purchased 
from the Jackson Laboratory. Heterozygous breeding of the mice generated the WT 
littermate controls.  
For the tumor studies, 1x105 luciferase-expressing 4T1 (Caliper Life Sciences) or 
4T1.1A4 cells (Xenogen) (used in combination study) were injected into the inguinal 
mammary fat pad of 8-10-week old female Balb/c mice (Charles River). Antibody 
treatment (i.p.) was started at day three after tumor inoculation and was given every 
second to third day until the end of the study with the following doses: anti-G-CSF 20 
μg/mouse (clone 67604, Cat: MAB414; R&D Systems), anti-CSF-1R 200 μg/mouse 
(AFS98, Cat: BE0213; BioXCell), IgG from rat serum (Sigma) control 200 μg/mouse in 
anti-CSF-1R and 220 μg/mouse in combination study. Tumor size was measured with a 
digital caliper and calculated using the formula Tarea=π/4 x larger diameter x smaller 
diameter. At the day of sacrifice, the mice were injected with 150 mg/kg of D-luciferin 
substrate (Caliper Life Sciences) and anesthetized after five minutes with a lethal dose 
(100 μL) of Narketan-Domitor 4:1 solution (ketamine 400 mg/kg and medetomidine 10 
mg/kg) or CO2. The blood was collected by cardiac puncture for flow cytometry or 
hematological analyses with Sysmex XT-2000iV, a flow cytometry device based on a 
sheath-flow and a semiconductor laser for an optical method for assessing white blood 
cell counts and differentiation (Clinical Laboratory of Veterinary Medicine, University of 
Zurich, Zurich, Switzerland). The lungs, liver and lymph nodes were excised and imaged 
(IVIS) after ten minutes with the following settings: exposure time=10 seconds (lungs), 
30 seconds (lymph nodes and liver), f/stop=1, medium binning, field of view=3.9×3.9 
cm2. Living Image software was used to quantify the bioluminescent signal reported as 
units of tissue radiance (photons/s/cm2/sr). 
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Tumor digestion  
Tumors were minced into 1-2 mm3 pieces and digested in digestion solution (10 mg/mL 
collagenase IV (Gibco), 20 μg/mL DNase (Invitrogen), 2.25 μM CaCl2 in PBS) in a shaker 
heated to 37°C. After 30 minutes, the tissue was filtered through a 40 μm cell strainer 
and flushed with 20 mL of MACS buffer (0.5% FBS, 2 mM EDTA in PBS). The single cell 
suspensions were analyzed for TAMs using flow cytometry. 
 
Statistical analyses 
Results are presented as mean ± SD. Statistical significance was determined as indicated 
in the figure legends. The analyses were performed and the graphs plotted in Prism V5.0 
(GraphPad Software), PASWStatistics 18.0 (SPSS Inc.) or Matlab version 7.12.0.635 
R2011a (Mathworks Inc.).  A P-value of  ≤ 0.05 was considered to be statistically 
significant. The results obtained using one-way ANOVA are presented by the ANOVA 
values in text and individual significances between groups are indicated by asterisks in 
the figures. Only the significant differences are indicated in figures by using * unless 
specifically marked as n.s. (not significant). *P≤0.05; **P≤0.01; ***P≤0.001. 
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Table 1. Clinico-pathological parameters of breast cancer samples on tissue microarrays 
with mixed breast carcinomas (n=641) and hormone receptor (ER/PgR) negative 
(n=91) carcinomas. 
  TMA mixed 
N=641 
TMA TN 
N=91 
Subtype 
 
Ductal 
Lobular 
Other 
missing 
474 (74%) 
79 (12%) 
62 (10%) 
26 (4%) 
78 (86%) 
3 (3%) 
0 
- 
Hormone 
receptor 
status 
ER positive 
ER negative 
missing 
473 (74%) 
103 (16%) 
65 (9%) 
0 
91 (100%) 
- 
HER2 status HER2 positive 
HER2 negative 
missing 
90 (14%) 
516 (80%) 
35 (6%) 
8 (9%) 
83 (91%) 
- 
Grade 1 
2 
3 
missing 
101 (16%) 
302 (47%) 
206 (32%) 
32 (5%) 
0 
5 (6%) 
86 (94%) 
- 
Axillary 
nodal status 
Positive 
Negative 
missing 
336 (52%) 
211 (33%) 
94 (15%) 
48 (53%) 
42 (46%) 
1 (1%) 
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Stadium 
 
pT1 
pT2 
pT3 
pT4 
missing 
266 (41%) 
267 (42%) 
48 (8%) 
33 (5%) 
27 (4%) 
38 (42%)  
44 (48%) 
7 (8%) 
2 (2%) 
- 
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Figure 1. MDA-MB-231 cells alternatively activate human CD14+ monocytes.  
A) Freshly isolated human CD14+ monocytes were cultured with three different breast 
cancer cell lines T47D (ER+), SKBR-3 (HER2+) and MDA-MB-231 (TN) in a transwell 
(tw.) co-culture system (ratio 1:1) and analyzed for changes in macrophage mannose 
receptor expression (MR) at indicated time points by immunofluorescence staining 
using anti-CD206 antibody (MR, red) and quantified as percentage of MR+ cells within 
the total number of CD68+ cells (green). Data were obtained from experiments 
performed in triplicates using four different monocyte donors and analyzed using One-
way ANOVA with Tukey’s multiple comparison test. Control wells (without cancer cells) 
contained RPMI alone (negative control) or 20 ng/mL IL-4 (positive control). B) 
Monocytes from the experiment in A) were incubated with DQ-ovalbumin for two hours 
prior to fixation at indicated time points and the signal from processed ovalbumin-
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BODIPY (green) was quantified as percentage of green cells to the number of Hoechst 
positive nuclei and analyzed using two-tailed Student’s t-test (n=3, data combined from 
three independent experiments with triplicate wells each). The arrows in the lower 
panel point to the processed ovalbumin signal indicated by BODIPY fluorescence, which 
was significantly decreased at day 5 compared to day 2 for monocytes cultured with 
MDA-MB-231 cells. Representative plots C) and histograms D) of flow cytometric 
analyses of cell surface HLA-DR and MR expression on CD14+ monocytes cultured in CM 
collected from three estrogen receptor positive cell lines (T47D, MCF-7 and BT-474) and 
two TNBC lines (Cal-51 and MDA-MB-231).  The monocytes were cultured (6 days) in 
ultra-low attachment plates to exclude the effect of adhesion on the expression levels of 
HLA-DR and MR. The grey-filled histogram represents the isotype control. Microscopic 
images of HLA-DR staining are shown on the right for MCF-7 and MDA-MB-231 CM 
cultured monocytes that were let to adhere overnight on culture slides. E) Graphs from 
the flow cytometric analysis (in D) showing the % of CD14+ cells positive for HLA-DR 
and MR. The expression of HLA-DR and MR on T47D cultured monocytes were selected 
as baseline to control for inter-individual variation. Statistical significance was analyzed 
using One-way ANOVA with Tukey’s multiple comparison test (n=3).  
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Figure 2. G-CSF is highly secreted by MDA-MB-231 cells and promotes 
differentiation of immunosuppressive HLA-DR low monocytes.  
A) Cytokine, chemokine and growth factor secretion analysis of CM of single cultured 
T47D, SKBR-3 and MDA-MB-231 cells using Bio-plex pro assay Human Cytokine 21-plex 
and Human Cytokine 27-plex. Error bars represent intra-assay variation between 
duplicate samples. B) Immunofluorescence images of human CD14+ monocytes cultured 
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for eight days in RPMI supplemented with either 1% human serum (AB) or 50 ng/mL 
recombinant human G-CSF (upper panel), MDA-MB-231 CM with 1 μg/mL of IgG control 
or anti-G-CSF (lower panel). MR expression was analyzed using anti-CD206 antibody 
(MR, red) and quantified as percentage of MR+ cells within the total number of CD68+ 
cells (green). Statistical analysis was done using two-tailed Student’s t-test (n=9, data 
combined from three independent experiments with triplicate wells). C) Representative 
plots of flow cytometric analyses of cell surface HLA-DR and MR expression on CD14+ 
monocytes cultured for four days (ultra-low attachment) in RPMI supplemented with 
1% human serum (AB) or 50 ng/mL recombinant human G-CSF. The histogram shows 
the percent of CD14+ cells that expressed lower levels of HLA-DR (Q4), n=5; Mann 
Whitney test. D) CFSE labeled CD4+ T-cells from tetanus toxoid vaccinated healthy 
donors were incubated for three days with donor matched CD14+ monocytes. The 
monocytes were collected four days prior T-cell co-culture to differentiate the cells with 
1% human serum (AB) or 50 ng/mL recombinant human G-CSF as in C and pulsed with 
tetanus toxoid for 3 h before addition of T-cells. T-cell proliferation was analyzed as the 
percent of cells appearing in the low CFSE gate by flow cytometry, n=4, mean from 
triplicate wells; two-tailed Student’s t-test. E) ELIspot assay of IFNγ production of CD4+ 
T-cells in response to tetanus toxoid in the presence of control (1% AB) or G-CSF (50 
ng/mL) differentiated monocytes as in (D), n=3, mean from triplicate wells.  
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Figure 3. G-CSF differentiated macrophages secrete TGF-α and selectively promote 
migration of EGFR expressing cells. A) Freshly isolated CD14+ monocytes were 
pretreated with 1% AB serum, T47D CM, MDA-MB-231 CM or 40 ng/mL hG-CSF in RPMI 
for 48 hours. The pre-incubation media was washed and replaced with RPMI only and 
conditioned for 24 hours. At this point the cancer cells were placed on the collagen 
coated upper chamber and cancer cell migration towards the pretreated monocytes was 
analyzed after six hours by counting the nuclei of transmigrated cells. The graphs 
represent the average number of Hoechst positive nuclei per 10x microscope field from 
three independent experiments done in triplicates and was analyzed using One-way 
ANOVA with Tukey’s multiple comparison test. B) ELISA analysis of TGF-α and 
Oncostatin M levels measured from monocyte pre-treatment CM (n=3) from the 
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experiment shown in A. Basal level of TGF-α and Oncostatin M in MDA-MB-231 CM is 
shown on graphs labeled MDA-MB-231 CM. MΦ CM (MDA) stands for CM from 
monocytes collected 24 hours after a 48 hour pre-treatment with MDA-MB-231 CM. 
Statistical analysis was done using One-way ANOVA with Tukey’s multiple comparison 
test. C) Western blot analysis of EGFR expression on T47D, MCF-7, Cal-51 and MDA-MB-
231 cells. EGFR signal intensity was quantified against tubulin expression in each 
sample and represented in the graph as arbitrary fluorescence units. D) Scratch wound 
migration of Cal-51 cells monitored every two hours for a total of 48 hours using the 
Incucyte ZOOM system. The Cal-51 cells were cultured in CM collected from monocytes 
grown in control medium or G-CSF as in figure 2C. The G-CSF activated monocyte CM 
was supplemented with 5 μg/mL of anti-TGFα or isotype control antibody before 
experimentation. Representative data from three independent experiments performed 
using CM from one monocyte donor where statistical significance was analyzed using 
two-way ANOVA.  
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Figure 4. High G-CSF expression is significantly associated with CD163+ TAMs and 
decreased overall survival in human TNBC.  
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A) Representative images of G-CSF staining from invasive tumor area (low staining 
intensity 0/1; high staining intensity 2/3) with hematoxylin and eosin counter staining 
(H&E). B) Quantification of G-CSF expression (staining intensity 0,1,2,3) in ER+/HER+ 
and triple-negative (TN) human breast cancer. The brackets above the graph represent 
statistical analysis between ER+/HER+ and TN groups using Chi-square test. C) Kaplan-
Meier curves of overall survival (OS) in TNBC patients expressing low G-CSF (0/1) vs. 
high G-CSF (2/3) (Log-Rank test). D) ELISA analysis of G-CSF levels on cancer 
conditioned medium of T47D, MCF-7, BT-474, Cal-51 and MDA-MB-231 cells. 1/2 and 
1/5 indicate the dilutions of MDA-MB-231 CM. Error bars represent intra-assay 
variation between duplicate samples. The dashed line at 20 pg/mL represents the 
detection limit of the assay. E) ELISA analysis of G-CSF levels and the corresponding cell 
viability of MDA-MB-231 cells after a 24- and 48-hour incubation with the MEK1/2 
inhibitor (RDEA) or MEK5 inhibitor (BIX). The G-CSF levels obtained from each well 
were normalized to cell viability to exclude the effect of cell number changes in G-CSF 
levels. The data is combined from 3-4 experiments performed in triplicates and analyzed 
using One-way ANOVA. F) Representative images of low and high CD68 staining and 
statistical analysis of CD163 expression in association with CD68 low and high patients 
using Chi-square test. G) Representative images of low and high CD163 staining and 
statistical analysis of CD163 expression in association with G-CSF low and high patients 
using Chi-square test. Two observers blinded to the identity of the samples performed 
the scoring of G-CSF samples independently. H) Representative images of TGF-α staining 
in whole tumor sections. The arrowheads indicate positive cells. The number of TGF-α 
positive cells in 5-10 40x microscopic fields were quantified from five G-CSF low and 
five G-CSF high patients and means are shown in the graph. Statistical significance was 
analyzed using two-tailed Student’s t-test.  
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Figure 5. G-CSF and M-CSF differentiated macrophages show similar activation. 
A) Flow cytometric analysis of cell surface G-CSF receptor expression on classical 
(CD14+CD16-), intermediate (CD14+CD16+) and non-classical (CD14dimCD16hi) human 
peripheral blood monocytes presented as geometric mean fluorescence intensity 
normalized to isotype control (gMFI; n=3); One-way ANOVA with Tukey’s multiple 
comparison test. B) Flow cytometric analysis of cell surface expression levels of 
activation markers CD16 (maturation), MR (M2), CD86 (M1), CD11c (M1), and CD80 
(M1) on human monocytes differentiated with 50 ng/mL G-CSF or M-CSF for eight days. 
The grey-filled line shows the isotype control in the histograms. The expression levels of 
D
ow
nl
oa
de
d 
by
 [T
ur
ku
 U
niv
ers
ity
] a
t 2
3:3
1 2
4 N
ov
em
be
r 2
01
5 
  51 
each marker in the graphs are presented as gMFIs and shown relative to the expression 
obtained from 1% AB serum treated monocytes from each donor (n=3), One-way 
ANOVA with Tukey’s multiple comparison test. C) Immunofluorescence images of M-CSF 
and G-CSF differentiated human macrophages (day 8) treated with DQ-ovalbumin two 
hours before fixation (green) and stained for MR (red). D) Flow cytometric analysis of 
DQ-ovalbumin processing in M-CSF and G-CSF treated macrophages at day 8. The 
control (M-CSF) indicates cells that were differentiated with M-CSF but not treated with 
DQ-ovalbumin. I, negative for DQ-OVA; II, positive for DQ-OVA.  
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Figure 6. Anti-CSF-1R treatment promotes metastasis in the 4T1 model. 
A) Growth curves of 4T1-luc mammary tumors treated with anti-CSF-1R (n=10) or IgG 
control (n=9) (both 200 µg/mouse every second day), Two-way ANOVA. B) On the day 
of sacrifice the lymph nodes, lung and liver were dissected from the treated mice 10 
minutes after a luciferin substrate injection and were imaged for metastatic burden 
using IVIS. The table shows metastasis positive organs on a yes/no basis, based on the 
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IVIS signal and are shown as metastasis positive/total number of mice. The lower 
graphs show the radiance signal for each organ. Significant outliers were excluded from 
statistical analyses based on Grubbs’ test and have been marked with a cross. Statistical 
significance was analyzed using two-tailed Student’s t-test with Welch’s correction. C) 
ELISA analysis of serum M-CSF levels from mice treated either with IgG or anti-CSF-1R, 
two-tailed Student’s t-test. D) End point hematological analysis of monocytes analyzed 
with Sysmex XT-2000iV in IgG and anti-CSF-1R treated mice. E) Immunofluorescence 
staining of tumor sections (peritumoral area) with anti-F4/80 (green) and anti-MR 
antibodies (red) in IgG and anti-CSF-1R treated mice. Quantification of double positive 
cells was done using ImageJ of 3-5 microscopic fields/mouse/treatment and analyzed 
using two-tailed Student’s t-test. F) Flow cytometric analysis of cell surface CSF-1R and 
G-CSFR expression on peripheral blood CD11b+Ly6C+ myeloid cells in C57BL/6 wild 
type (WT) and G-CSFR knockout (KO) mice where gate Q1 represents the monocytic 
population (Ly6G-) and gate Q3 the granulocytic population (Ly6G+). Because we used 
human recombinant G-CSF conjugated with AlexaFluor488 (G-CSF-488) for the 
detection of G-CSFR the G-CSFR KO mice served as a control for specific binding of the 
protein. The histograms show binding of G-CSF-488 to the monocytic and granulocytic 
populations in WT (black line) and KO (grey-filled line) mice. G) Flow cytometric 
analysis of cell surface CSF-1R and G-CSFR expression on peripheral blood CD11b+Ly6C+ 
myeloid cells in Balb/c mice without tumors or carrying a 4T1 tumor (size 5x5 mm). As 
in (F) the Q3 gate served as a positive cell population for G-CSFR expression, and is 
shown as the grey-filled histograms. Note that the 4T1 tumor induced a granulocytic cell 
population double positive for CSF-1R and G-CSFR (Q2). 
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Figure 7. Combination treatment of blocking both CSF-1R and G-CSF reduces lung 
metastasis but promotes lymph node metastasis via depletion of CD169+ 
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subcapsular sinus macrophages. 
A) Growth curves of 4T1.1A4-luc mammary tumors treated with IgG control (n=8, 220 
µg/mouse), anti-CSF-1R (n=7, 200 µg/mouse), anti-G-CSF (n=8, 20 µg/mouse) or 
combination treatment (n=9, anti-CSF-1R 200 µg/mouse and anti-G-CSF 20 µg/mouse).  
Statistical analysis was done using two-way ANOVA. B) On the day of sacrifice, the 
lymph nodes, lung and liver were dissected from the treated mice 10 min after a 
luciferin substrate injection and imaged for metastatic burden using IVIS. The upper 
numbers show metastasis positive organs on a yes/no basis based on the IVIS signal and 
are shown as metastasis positive/total number of mice. The asterisk indicates significant 
reduction in metastasis compared to IgG control and was analyzed using Fisher’s exact 
test. The lower graphs show the radiance signal for each organ. Significant outliers were 
excluded from statistical analyses based on Grubbs’ test and have been marked with a 
cross. C) The effect of the different treatments on blood myeloid cell populations in 
tumor bearing mice were analyzed by flow cytometry based on CD11b+ and further 
gated for monocytic cell populations using Ly6C and granulocytic cell populations using 
Ly6G. The anti-G-CSF plots were used for the gating strategy of the different blood 
myeloid cell populations since it normalized blood monocytic cell differentiation (Ly6int-
lo; see also Supplemental Figure 5A). From this gating strategy the gates marked as red 
show detailed analysis of five mice/treatment for the % of CD11b cells in these gates 
(Ly6CintLy6Glo and Ly6CloLy6Glo). The gates marked as blue show detailed analysis of 
cell surface MHCII expression on Ly6Chi and Ly6Cint monocytes between treatments. D) 
Different TAM populations were analyzed using the gating strategy previously reported 
by Movahedi et al., 52 where CD11b+ cells are gated further using Ly6C and MHCII to 
identify anti-inflammatory TAMs (Ly6CloMHCIIlo) and pro-inflammatory TAMs 
(Ly6CloMHCIIhi). The gates marked as red show detailed analysis of five mice/treatment 
D
ow
nl
oa
de
d 
by
 [T
ur
ku
 U
niv
ers
ity
] a
t 2
3:3
1 2
4 N
ov
em
be
r 2
01
5 
  56 
for the % of CD11b that have low and high MHCII expression. The anti-G-CSF treated 
TAMs formed a population of Ly6CintMHCIIlo cells (blue gate) that were further analyzed 
for the expression of activation markers F4/80 and MR (mean fluorescence intensity, 
MFI) between treatment groups. E) Immunofluorescence images of lymph nodes stained 
with anti-CD169 (green) to identify the effect of the different treatments on subcapsular 
sinus macrophages. The white dashed line indicates the LN border. All statistical 
significances were tested using One-way ANOVA with Tukey’s multiple comparison test 
unless otherwise stated.  
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